Komori
COSMOS Pharmaceutical (3349) · RiskDropped

Increased Uncertainty over the Outlook Due to the Spread of COVID-19

First written in FY2020-Q3. 8 of 14 entries say "Restated". Latest entry: FY2023.

14entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2021-Q1 – FY2021-Q3RestatedFY2023-Q1 – FY20232020: 320202021: 420212022: 420222023: 32023
Same theme, other companies
Economic slowdown and decline in customer demand due to COVID-19A theme 192 companies write about · 192 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2020: 111 of 174 companies on the "Worse" side.

55 other companies' latest entry also says "Dropped".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 192 companies compared. The sentences above are computed from all 192.
Full recordFilings, disclosures and news, newest first
  1. FY2023DroppedAnnual report
    The explanation of the economic environment, business risks and additional information for the fiscal year contains no explicit reference to the previously described impact of the spread of COVID-19.
  2. FY2023-Q3RestatedAnnual report

    「There have been no material changes to the assumptions concerning the impact of COVID-19 described in the additional information to the annual securities report for the previous consolidated fiscal year.」

    The Company reconfirms that there have been no material changes to its existing assumptions concerning the impact of COVID-19.
  3. FY2023-Q2RestatedAnnual report

    「There have been no material changes to the assumptions concerning the impact of COVID-19 described in the additional information to the annual securities report for the previous consolidated fiscal year.」

    The Company reconfirms that there have been no material changes to its assumption that the impact of COVID-19 will continue.
  4. FY2023-Q1RestatedAnnual report

    「There have been no material changes to the assumptions concerning the impact of COVID-19 described in the additional information to the annual securities report for the previous consolidated fiscal year.」

    The Company states that there have been no material changes to its assumption that the impact of COVID-19 will continue.
  5. FY2022WorsenedAnnual report

    「The Group assumes that, although the impact of COVID-19 is gradually subsiding, it will continue through the fiscal year ending May 2023.」

    The Company assumes that the impact of COVID-19 will continue through the fiscal year ending May 2023, extending the assumed impact period from the previous assumption that it would continue through the fiscal year ending May 2022.
  6. FY2022-Q3RestatedAnnual report

    「There have been no material changes to the assumptions concerning the impact of COVID-19 described in the additional information to the annual securities report for the previous consolidated fiscal year.」

    The Company states that there have been no material changes to its assumption that the impact of COVID-19 will continue.
  7. FY2022-Q2WorsenedAnnual report

    「また、ワクチン接種は進行しているものの、新たな変異株が確認されるなど、今後も経済の先行きが見通せない厳しい状況が続くと想定されます。」

    Regarding the spread of COVID-19, the Company states that new variants have been identified even as vaccination progresses, and recognizes that severe conditions in which the economic outlook cannot be forecast will continue.
  8. FY2022-Q1RestatedAnnual report

    「There have been no material changes to the assumptions concerning the impact of COVID-19 described in the additional information to the securities report for the previous consolidated fiscal year.」

    The Company states that there have been no material changes to its assumption that the impact of COVID-19 will continue.
  9. FY2021WorsenedAnnual report

    「The Company assumes that the impact of COVID-19 will continue through the fiscal year ending May 2022, although this assumption may vary depending on when the situation comes to an end.」

    The Company assumes that the impact of COVID-19 will continue through the fiscal year ending May 2022, extending the assumed impact period from the previous fiscal year ending May 2021.
  10. FY2021-Q3RestatedAnnual report

    「当第3四半期連結累計期間(2020年6月1日~2021年2月28日)におけるわが国の経済は、新型コロナウイルスの感染拡大に伴い政府や各地方自治体が外出自粛要請等を発信したことにより、企業活動や個人消費が大きく収縮する事態が生じました。また、2021年1月には一部地域で緊急事態宣言が再発出されるなど、経済の先行きにつきましては今後も不透明な状況が続くと想定されます。」

    The Company continues to recognize that the contraction in business activity and personal consumption caused by the spread of COVID-19, and the resulting adverse impact on the economy, will continue. It states that there have been no material changes to the assumptions, including the expected timing of the end of the pandemic, described in the additional information.
  11. FY2021-Q2RestatedAnnual report

    「当第2四半期連結累計期間におけるわが国の経済は、新型コロナウイルスの感染拡大に伴い政府や各地方自治体が外出自粛要請等を発信したことにより、企業活動や個人消費が大きく収縮する事態が生じました。これによる経済への悪影響は、しばらく続くものと予想しております。」

    The Company continues to recognize that the contraction in business activity and personal consumption caused by the spread of COVID-19, and the resulting adverse impact on the economy, will continue.
  12. FY2021-Q1RestatedAnnual report

    「During the first quarter of the current consolidated cumulative period, Japan's economy contracted sharply as the spread of COVID-19 led the government and local authorities to issue requests for people to refrain from going out, causing business activity and personal consumption to shrink substantially. We expect the adverse impact on the economy to continue for some time.」

    The Company states that the contraction in business activity and personal consumption caused by the spread of COVID-19, and the resulting adverse impact on the economy, will continue. It states that there have been no material changes to the assumptions, including the expected timing of the end of the pandemic, described in the annual securities report for the previous consolidated fiscal year.
  13. FY2020MaterialisedAnnual report

    「Business and consumer activity has been affected by the spread of COVID-19, and uncertainty about the outlook continues. If the situation is prolonged, it may affect the performance of the Group, including transactions and new store openings. The Group assumes that the impact of COVID-19 will continue through the fiscal year ending May 2021, although this assumption may vary depending on when the situation comes to an end.」

    The Company formally identifies the impact of COVID-19 as a risk and assumes that it will continue through the fiscal year ending May 2021. It also describes store closures caused by the slowdown in inbound demand and the impact on new store openings and transactions.
  14. FY2020-Q3First statedAnnual report

    「During the nine-month period ended 29 February 2020, the Japanese economy became difficult to forecast because of the cooling effect of the consumption tax increase on consumer sentiment and the spread of COVID-19.」

    The company first explicitly stated that the spread of COVID-19 had made the economic outlook difficult to predict. The outbreak and its impact on the economic environment had already occurred, but no specific impact on the company’s earnings was disclosed.
Moved together

"Impact of Natural Disasters on Stores and the Distribution Network" moved the same way as this thread, in the same document, in 3 of its 14 moves.

332★123
  1. ★This thread
  2. 1Impact of Natural Disasters on Stores and the Distribution Network3×
  3. 2Revenue and Profit Growth and Expansion of Operating Cash Flow3×
  4. 3Cost-consciousness and Intensifying Competition in the Drugstore Industry2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for COSMOS Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Increased Uncertainty over the Outlook Due to the Spread of COVID-19 | COSMOS Pharmaceutical Corporation (3349) | Komori